Key word.~: Gene transfer: Plasmid; Liposome: Central nervous system: Murine Gene transfer to the central nervous sysiem (CNS) is complicated by the anatomic and physiologic isolation of thc brain. Direct injection techniques circumvent this, and allow delivery of transgenes to specific areas of the CNS. Previously. direct transfection of cellular component,~ of the CNS has been achieved using plasmid DNA. We report the use of cationic liposomes as a means oftransfecting plasmids into adult mammalian brain. Using the gent fi~r E. co/i fl-galactosidase or the eDNA or human ,B-glucuronidase as reporters, we demonstrate plasmid mediated gene transfer into the caudate putamen of adul( mice with expression of the transgene for at least 21 days posl-transfection.
Regional alteration of brain function by directed gene transfer may allow for the investigation and treatment of both inherited and acquired diseases of brain. Examples of inherited CNS diseases that may be investigated by regional gene transfer include the mucopolysaccharidoses (MPS). a group of lysosomal storage diseases characterized by the accumulation of glycosaminoglycans within the neuroglial cells of the CNS [16] . Enzymatic correction directed to the CNS of animals with MPS would allow the analysis of the biochemical, histological and functional effects associated with transgene expression. Further, since metabolic cooperation occurs between various cell types within the brain, a regional correction of MPS deficiency may produce a more diffuse level of biochemical and/or functional improvement. On the other hand, neurodegenerative conditions such as Parkinson's or Alzheimer's are acquired diseases that exhibit a characteristic regional neuropathology, and amelioration of CNS manifestation may result from the regional expression of specific gene products [6, 23] . These hypotheses could be tested by the development of methods to mediate the production of transgenic proteins in anatomically defined brain regions.
Gene transfer to specific brain regions may be approached by direct somatic cell gene transfer. Since adult mammalian CNS cells do not readily undergo cell division and are long lived, they represent an ideal target for somatic cell gene transfer. Previous efforts at somatic cell *Corresponding authors. Fax: ( I ) (313) 763-4151.
SSDI 0304-3940(93 )E08 1 3-B gene transfer to the CNS have focused on the use of replication defective herpesviruses, retroviruses or adenoviruses [4, 11, 18, 19, 25] . As an alternative to these viral based methods, eukaryotic expression plasmids may also be used as vehicles for gene transfer in vivo [17] . Theoretically, the use of plasmids may be superior to replication deficient viral vectors because there is no associated risk of productive viral infection or additional adverse effects such as cell death, autoimmune encephalitis or intracranial spread of the viral vectors to non-targeted regions of the brain, in addition, non-integrating episomally persistent plasmids reduce the possibility that transfected cells would undergo neoplastic transformation.
Cationic liposomes are an established system lot the delivery of genetic material into eukaryotic cells both in vitro and in vivo [9, 10, 17] . In vivo liposomes have been used to transfect cells of the vertebrate embryonic CNS using plasmid DNA [10] . Additionally. previous studies using plasmids and cationic liposomes in vivo have shown successful gene transfer into CNS neurons of neonatal mice (age 7 days) with expression of transgenes for up to 9 days post transfection [I 7] . The in vivo expression of plasmid transgenes in the brains of mature rodents has also been achieved by transplantation of transfected pluripotent embryonic stem cells into adult rats or by direct hippocampal injection for I 5 days past treatment [13, 15] . To test methods of in vivo plasmid mediated gene transfer into adult brains, we used high concentrations of plasmid DNA and a modification of a commercially available cationic liposome preparation to transfeet adult murine brain cells in vivo. Expression of two distinct transgenes was evident for at least 21 days post transfection. This is the first report of the successful use of cationic liposomes and plasmids to mediate gene transfer of lysosomal enzymes to the brains of fully developed adult mammals.
In these experiments we used eukaryotic expression plasmids containing strong viral promoters: the SV40 promoter or the LTR promoter derived from the Moloney murine leukemia virus (MMLV). These promoters were chosen in order to increase short-term transgene transcription and thus to enhance the detection of transgenic protein expression in situ. In addition, the experiments used two functional reporter transgenes, these included the gene for E. coli fl-galactosidase (lacZ), and the eDNA for human ]~-glucuronidase. Human fl-glucuronidase is a lysosomal enzyme that is required for proper metabolic degradation of an entire class of mucopolysaccharides. Complete deficiency of this enzyme is associated with Sly's syndrome (MPS Vii), a rare but typical mucopolysaccharidosis characterized by the lysosomal accumulation of glycosaminoglycans within the CNS, resulting clinically in mental retardation and severe neurological dysfunction [2, 22] . A naturally occurring autosomal recessive murine model of this condition exists, the gusm~/gus m~ mouse [3, 25] . These animals are a prototypic model for lysosomal storage diseases and provide a system to test the applicability of plasmid/liposome mediated gene transfer to brain for the treatment of inherited enzymopathies.
Three distinct eukaryotic expression plasmids were used in these experiments. The plasmid pSGSlacZ, that contains the lacZ gene under transcriptional control of an SV40 promoter (derived from pSG5: Stratagene). The plasmid pMFGlacZ, that contains the lacZ gene under transcriptional control of MMLV based LTR [5] , and the plasmid pSGShflg, which contains the eDNA for human fl-glucuronidase under transcriptional control of an SV40 promoter.
In each experiment 25 gg of purified plasmid was used for intracranial injection. Purified pMFGlacZ. pSG51acZ or pSG5hflg were lyophilized and resuspended in 2.5/,d of 20% sucrose in phosphate buffered saline (PBS). This DNA solution was then combined with 2.5/zl of undiluted lipofectin reagent (Betbesda Research Laboratories), and incubated at 37°C for l0 rain. Controls consisted of lipofectin reagent alone or lipofectin reagent combined with pSG5 (25 gg in 2.5 gl PBS/ 20% sucrose).
In the case of the lacZ plasmids, recipient animals were 7 week old C3H/HeJ mice. In the case offl-glucuronidase plasmids, recipient animals were 7 week old beterozygous deficient gus m~÷ mice [3, 25] . The plasmid/liposome preparations were then injected into the righ! cerebral hemisphere in the region of the caudate putamen using a stereotactic platform (David Kopf Instruments). Injections were made using a 25,ul Hamilton syringe and a 30 gauge needle over a l0 rain period (injection rate 0.5 gl/ min). Mice were observed for 1-4 weeks alter injection and were periodically sacrificed for analysis of transgene expression. No clinical evidence of brain dysfunction or systemic disease was observed in the experimental animals throughout the 4 week observation period.
Mice injected with plasmids containing lacZ and lipofectin, or lipofectin alone, were systemically perfused with 2% paraformaidehyde in 100 mM PIPES pH 6.9 with 2 mM MgCl:. Brains were removed, blocked, and post fixed for 2 h. The blocks were then cryoprotected in 30% sucrose in PBS. Forty micron cryostat sections were mounted onto coated slides, fixed in 0.5% glutaraldehyde in PBS for 5 min, and rinsed twice in PBS with I mM MgCl:. Slides were then reacted for 4 h in X-gal in PBS [24] . Sections were then counterstained with Neutral red, mounted under Permount (Fischer Scientific) and examined by light microscopy.
Mice injected with pSGShflg and lipot~ctin or lipofectin controls were systemically perfused with PBS and the brains were removed and fresh frozen in OCT (Sigma). Cryostat sections (6 gm) were obtained from the region of injection and stained for fl-glucuronidase activity using a chromogenic substrate [3] . Transfected cells can be easily distinguished within the heterozygous background due to the relatively low levels of endogenous m urine fl-glucuronidase produced in the CNS. Sections were stained for fl-glucuronidase activity as previously described [3] , and mounted under Permount (Fischer Scientific) and examined by light microscopy.
Examination of the brains from mice treated with both pSGSlacZ/iipofectin and pMFGlacZ/lipofectin showed the presence of blue staining cells, indicating intracellular expression of the lacZ transgene (Fig. I A--D ). There were no qualitative differences in transfection efficiency or regional tropism observed between pSGSlacZ/lipofectin and pMFGlacZ/lipofectin, in both cases, blue cells were largely confined to an area along the needle track that morphologically included cells within areas of the neocortex, corpus caliosum, and caudate putamen. LacZ positive cells were observed in multiple serial sections and were also observed in the area of the hippocampal ridge slightly removed from the injection point (Fig. ! B) . No blue cells were seen in the contralateral hemispheres of these animals, nor in the brains ofanimals treated with liposome alone or liposome combined with an irrelevant plasmid (data not shown). Cells expressing the lacZ transgene persisted at 3 weeks (Fig. ID) . but were not detected at 4 weeks post injeclion (data not shown). Although mouse brains injected with the plasmid/liposome preparation did not exhibit evidence for extensive necrosis, or alteration of normal brain architecture (Fig. 1L it is known that non-specific brain injury may be associated with a reactive gliosis. In addition, because some types of glial cells are derived from cells of monocyte/macrophage lineage, these reactive cells may express endogenous levels of lysosomal ,B-galactosidase and may produce a false positive signal when using X-gal as a chromogenic substrate. Thus, specific plasmid mediated transgene expression in vivo was confirmed using the plasmid pSG5h,Bg (containing the human ,B-glucuronidase eDNA) combined with lipofectin. Examination of heterozygous deficient gus "v~÷ mice I week post injection with pSG5h,Bg/lipofectin confirmed specific plasmid mediated transgene expression within the CNS. Red staining cells were present in the CNS of mice injected with pSG5h/~g/lipofectin (Fig 2A-C) , but were absent from control animals (Fig. 2D) .
In addition to the positively staining neurons seen in the neocortex, we attempted to identify transfected neuroglia by transmission electron microscopy (TEML We further processed sections of X-gal stained tissues which were positive for gene transfer for TEM [4] , and identified cell types based upon established ultrastructural criteria. Ultrathin sections were obtained and alternate sections were stained with 2% uranyl acetate and lead citrate. Examination of brain tissues treated with pSG51acZ/liposome by TEM revealed that in vivo transfection was accomplished within multiple neuroglia, as evidenced by the presence of spicules indicative of X-gal reaction product (Fig. 3} . Plasmid/liposome transfection in vivo was confined to the stereotactically targeted regions of the brain, with no evidence of contralateral transgene expression. The use of plasmid/liposome preparations was not associated with clinical evidence of brain injury or morphologic evidence of necrosis or inflammation. This contrasts with previous results obtained using replication defective recombinant herpes viruses, vectors that continue to ex- hibit cytopathic effects in vivo, and may be associated with spread of the virus to non-targeted brain regions via anterograde or retrograde axonai transport [1, 8, 11, 25] . The experiments using lacZ as a reporter gene support the short-term efficacy of this system to mediate transgene expression. Those experiments demonstrating direct in vivo gene transfer and expression of human flglucuronidase via an eukaryotic expression plasmid in the brains of heterozygous deficient gus "p~* support the concept that therapeutically relevant genes can be delivered to specific regions of the adult brain using this system.
The plasmids used in these experiments contained strong viral promoters to assure high level short-term transgene expression. Both promoters were able to mediate CNS transgene expression and no qualitative differences were observed in the activity of the two promoters. However, the SV40 and MMLV LTR viral promoters have both been associated with the temporal extinction of transgene expression in the context of herpes or adenoviral systems [4, 8, 11, 12, 20, 21, 25] . The results of these studies (progressive loss of transgene expression by 4 weeks post-transfection) are consistent with the previously described behavior of these viral promoters in vivo. Additional experiments using expression plasmids that contain cell specific constitutive promoters in an attempt to enhance the persistence of transgene expression in vivo are currently underway.
Previous studies have shown that the ratio of plasmid DNA to cationic liposome that produces an optimal transfection efficiency is largely empiric and must be optimized for individual in vitro applications [7, 14] . It follows that similar empiric parameters must also be used for the optimization of transfection efficiency for in vivo delivery systems. The goals of these initial studies were to determine if expression plasmids combined with cationic liposomes can be used for transfection of adult brain cells in vivo. Thus, we utilized the maximum amount of 
